AbbVie Q3 2026 Earnings: EPS More Than Doubles Year Over Year
AbbVie posted strong third-quarter results with both GAAP and adjusted diluted EPS surging more than 100% from a year earlier.
AbbVie reported third-quarter 2026 financial results that showed diluted earnings per share more than doubling on both a GAAP and adjusted basis compared to the same period a year ago, the pharmaceutical company announced.
On a GAAP basis, diluted EPS came in at $2.37, representing growth of more than 100 percent year over year. Adjusted diluted EPS reached $3.82, also reflecting an increase exceeding 100 percent, signaling broad-based improvement in the company's underlying profitability.
Read more Strathcona Resources Posts Q3 2026 Results, Raises Dividend 7% →
Both figures were modestly weighed down by acquisition-related costs. AbbVie noted an unfavorable impact of $0.11 per share tied to acquired in-process research and development charges as well as milestone expenses, a recurring consideration for large pharmaceutical companies that actively pursue licensing deals and external pipeline assets.
The scale of the year-over-year earnings surge suggests the prior-year comparable period was materially depressed, a dynamic that can occur when a company absorbs significant one-time charges or faces transitional revenue pressures. AbbVie has been navigating a post-Humira revenue landscape, diversifying its portfolio through newer immunology and oncology assets, though the source did not specify which products drove this quarter's performance.
Continue reading at Earnings.
